Clinical Trials Browser

Phase 1/2 × NSCLC × pembrolizumab × Clear all

NCT03562871 2022-04-21

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

Phase 1/2 Completed

NSCLC